Long-term follow-up of an IgA nephropathy cohort: outcomes and risk factors

References

• Schena F, Nistor I. Epidemiology of IgA nephropathy: a global perspective. Semin Nephrol. 2018;38(5):435–442.
   PubMed Web of Science ®Google Scholar
• Mazzuchi N, Acosta N, Caorsi H, et al. Programa de prevención y tratamiento de las glomerulopatías. Frecuencia de diagnóstico y de presentación clínica de glomerulopatías en Uruguay. Nefrologia. 2005;25:113–120.
   PubMedGoogle Scholar
• Garau M, Cabrera J, Ottati G, et al. Temporal trends in biopsy-proven glomerular disease in Uruguay, 1990–2014. PLoS One. 2018;13(10):e0206637.
   PubMed Web of Science ®Google Scholar
• Pattrapornpisut P, Avila-Casado C, Reich HN. IgA nephropathy: core curriculum 2021. Am J Kidney Dis. 2021;78(3):429–441.
   PubMed Web of Science ®Google Scholar
• Coppo R, Troyanov S, Bellur S, et al. Validation of the oxford classification of IgA nephropathy in cohorts with different presentations and treatments. Kidney Int. 2014;86(4):828–836.
   PubMed Web of Science ®Google Scholar
• Barbour SJ, Coppo R, Zhang H, et al. Evaluating a new international risk-prediction tool in IgA nephropathy. JAMA Intern Med. 2019;179(7):942–952.
   PubMed Web of Science ®Google Scholar
• Barbour SJ, Canney M, Coppo R, et al. Improving treatment decisions using personalized risk assessment from the international IgA nephropathy prediction tool. Kidney Int. 2020;98(4):1009–1019.
   PubMed Web of Science ®Google Scholar
• Cattran DC, Coppo R, Cook HT, et al. The oxford classification of IgA nephropathy: rationale, clinicopathological correlations, and classification. Kidney Int. 2009;76(5):534–545.
   PubMed Web of Science ®Google Scholar
• Zhang J, Huang B, Liu Z, et al. External validation of the international IgA nephropathy prediction tool. Clin J Am Soc Nephrol. 2020;15(8):1112–1120.
   PubMed Web of Science ®Google Scholar
• Rovin BH, Adler SG, Barratt J, et al. Executive summary of the KDIGO 2021 guideline for the management of glomerular diseases. Kidney Int. 2021;100(4):753–779.
   PubMed Web of Science ®Google Scholar
• Floege J, Rauen T, Tang S. Current treatment of IgA nephropathy. Semin Immunopathol. 2021;43(5):717–728.
   PubMed Web of Science ®Google Scholar
• Lennartz DP, Seikrit C, Wied S, et al. Single versus dual blockade of the renin-angiotensin system in patients with IgA nephropathy. J Nephrol. 2020;33(6):1231–1239.
   PubMed Web of Science ®Google Scholar
• Coppo R. Treatment of IgA nephropathy: recent advances and prospects. Nephrol Ther. 2018;14(1):s13–S21.
   PubMedGoogle Scholar
• Natale P, Palmer SC, Ruospo M, et al. Immunosuppressive agents for treating IgA nephropathy. Cochrane Database Syst Rev. 2020;3(3):CD003965.
   PubMedGoogle Scholar
• Rauen T, Wied S, Fitzner C, et al. After ten years of follow-up, no difference between supportive care plus immunosuppression and supportive care alone in IgA nephropathy. Kidney Int. 2020;98(4):1044–1052.
   PubMed Web of Science ®Google Scholar
• Seikrit C, Rauen T, Stamellou E, et al. Precision medicine in immunoglobulin a nephropathy: still a journey ahead. Nephrol Dial Transplant. 2021;36(2):24–30.
   PubMedGoogle Scholar
• Haas M, Verhave JC, Liu ZH, et al. A multicenter study of the predictive value of crescents in IgA nephropathy. J Am Soc Nephrol. 2017;28(2):691–701.
   PubMed Web of Science ®Google Scholar
• Trimarchi H, Haas M, Coppo R. Crescents and IgA nephropathy: a delicate marriage. JCM. 2022;11(13):3569.
   Google Scholar
• Guías de Práctica clínica en el tratamiento de las glomerulopatías. Uruguay. Ed Cuadrado. 2017. https://www.nefrologia.hc.edu.uy/images/Guias_de_Practica_clinica_para_tratamiento_de_las_Glomerulopatias._Version_2018.pdf
   Google Scholar
• Levey AS, Stevens LA. Estimating GFR using the CKD epidemiology collaboration (CKD-EPI) creatinine equation: more accurate GFR estimates, lower CKD prevalence estimates, and better risk predictions. Am J Kidney Dis. 2010;55(4):622–627.
   PubMed Web of Science ®Google Scholar
• Trimarchi H, Barratt J, Cattran DC, et al. Oxford classification of IgA nephropathy 2016: an update from the IgA nephropathy classification working group. Kidney Int. 2017;91(5):1014–1021.
   PubMed Web of Science ®Google Scholar
• Kasamatsu E, Nunes V, Morán M, et al. Glomerulopatías en el Paraguay. Reporte del registro de biopsias renales en 1072 casos. Mem Inst Invest Cienc Salud. 2005;3(1):51–57.
   Google Scholar
• Arias LF, Henao J, Giraldo RD, et al. Glomerular disease in a Hispanic population: review of a renal biopsy database. Sao Paulo Med J. 2009;127(3):140–144.
   PubMed Web of Science ®Google Scholar
• Lima H, Deboni L, Silva V, et al. Distribution of kidney diseases in Joinville, Santa Catarina analysis of a kidney biopsy data bank between 2008 and 2019. J Bras Nefrol. 2022;44(3):358–367.
   PubMedGoogle Scholar
• Navarro B, Brandao M, Sanches MF, et al. IgA nephropathy in Salvador, Brazil. Clinical and laboratory presentation at diagnosis. Braz J Nephrol. 2018;40(3):242–247.
   Google Scholar
• Dos-Santos WLC, Sweet GMM, Azevêdo LG, et al. Current distribution pattern of biopsy-proven glomerular disease in salvador, Brazil, 40 years after an initial assessment. J Bras Nefrol. 2017;39(4):376–383.
   PubMedGoogle Scholar
• García-Herrera H, Restrepo V, Augusto C, et al. Características clínicas e histológicas de las enfermedades parenquimatosas renales en una muestra de biopsias renales obtenidas entre el año 2002 y el 2017 en el departamento de Caldas, Colombia. Revista Colombiana de Nefrología. 2018;5(2):107–117.
   Google Scholar
• Benítez Llanes O, Guerra Bustillo G, Castañer Moreno J, et al. Indicadores de predicción evolutiva en la nefropatía primaria por inmunoglobulina A. Estudio cooperativo. Rev Cub Med. 2006;45(2). http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S0034-75232006000200005&lng=es&tlng=es/(accesed 27 November 2022).
   Google Scholar
• O’Shaughnessy M, Hogan S, Thompson B, et al. Glomerular disease frequencies by race, sex and region: results from the international kidney biopsy survey. Nephrol Dial Transplant. 2018;33(4):661–669.
   PubMed Web of Science ®Google Scholar
• Bucheli M, Cabeda W. Perfil demográfico y socioeconómico de la población uruguaya según su ascendencia racial. Informe temático. 2006. https://www.ine.gub.uy/documents/10181/35933/Informe+final+raza.pdf/c2265907-d8a0-45fe-8b52-d231faa65c59
   Google Scholar
• Moriyama T, Tanaka K, Iwasaki C, et al. Prognosis in IgA nephropathy: 30 years analysis of 1012 patients at a single center in Japan. PLoS One. 2014;9(3):e91756.
   PubMed Web of Science ®Google Scholar
• Moriyama T, Karasawa K, Miyabe Y, et al. Validation of the revised oxford classification for IgA nephropathy considering treatment with corticosteroids/immunosuppressors. Sci Rep. 2020;10(1):11151.
   PubMed Web of Science ®Google Scholar
• Lv J, Yang Y, Zhang H, et al. Prediction of outcomes in crescentic IgA nephropathy in a multicenter cohort study. J Am Soc Nephrol. 2013;24(12):2118–2125.
   PubMed Web of Science ®Google Scholar
• Gadola L, Cabrera J, Acosta Marichal N, et al. Nefropatía IgA en Uruguay. Rev Méd Urug. 2015;31:15–16.
   Google Scholar
• Komatsu H, Fujimoto S, Sato Y, et al. “Point of no return (PNR)” in progressive IgA nephropathy: significance of blood pressure and proteinuria management up to PNR. J Nephrol. 2005;18(6):690–695.
   PubMed Web of Science ®Google Scholar
• Reich HN, Troyanov S, Scholey JW, et al. Remission of proteinuria improves prognosis in IgA nephropathy. J Am Soc Nephrol. 2007;18(12):3177–3183.
   PubMed Web of Science ®Google Scholar
• Le W, Liang S, Hu Y, et al. Long-term renal survival and related risk factors in patients with IgA nephropathy: results from a cohort of 1155 cases in a Chinese adult population. Nephrol Dial Transplant. 2012;27(4):1479–1485.
   PubMed Web of Science ®Google Scholar
• Thompson A, Carroll K, Inker L, et al. Proteinuria reduction as a surrogate end point in trials of IgA nephropathy. Clin J Am Soc Nephrol. 2019;14(3):469–481.
   PubMed Web of Science ®Google Scholar
• Inker LA, Heerspink HJL, Tighiouart H, et al. Association of treatment effects on early change in urine protein and treatment effects on GFR slope in IgA nephropathy: an individual participant meta-analysis. Am J Kidney Dis. 2021;78(3):340–349.e1.
   PubMed Web of Science ®Google Scholar
• Berthoux F, Mohey H, Laurent B, et al. Predicting the risk for dialysis or death in IgA nephropathy. J Am Soc Nephrol. 2011;22(4):752–761.
   PubMed Web of Science ®Google Scholar
• Ruan Y, Hong F, Wu J, et al. Clinicopathological characteristics, risk factors and renal outcome in IgA nephropathy with crescents. J Nephrol. 2022;35(4):1113–1121.
   PubMed Web of Science ®Google Scholar
• Ma F, Liu L, Dong R, et al. Renal survival and risk factors in IgA nephropathy with crescents. Int Urol Nephrol. 2020;52(8):1507–1516.
   PubMed Web of Science ®Google Scholar
• Chen CH, Wu MJ, Wen MC, et al. Crescents formations are independently associated with higher mortality in biopsy-confirmed immunoglobulin a nephropathy. PLoS One. 2020;15(7):e0237075.
   PubMed Web of Science ®Google Scholar
• Ştefan G, Ismail G, Stancu S, et al. Validation study of oxford classification of IgA nephropathy: the significance of extra capillary hypercellularity and mesangial IgG immunostaining. Pathol Int. 2016;66(8):453–459.
   PubMed Web of Science ®Google Scholar
• Haaskjold YL, Lura NG, Bjørneklett R, et al. Validation of two IgA nephropathy risk-prediction tools using a cohort with a long follow-up. Nephrol Dial Transplant. 2022;gfac225. DOI: 10.1093/ndt/gfac225
   PubMed Web of Science ®Google Scholar
• Zhang W, Zhou Q, Hong L, et al. Clinical outcomes of IgA nephropathy patients with different proportions of crescents. Medicine (Baltimore). 2017;96(11):e6190.
   PubMed Web of Science ®Google Scholar
• Liang M, Xiong L, Li A, et al. The effectiveness and safety of corticosteroid therapy for IgA nephropathy with crescents: a prospective, randomized, controlled study. BMC Nephrol. 2022;23(1):40.
   PubMed Web of Science ®Google Scholar
• Chen J, Xu H, Peng Z, et al. Efficacy of corticosteroids in immunoglobulin a nephropathy with less than 25% crescents. Clin Exp Nephrol. 2020;24(1):73–81.
   PubMed Web of Science ®Google Scholar
• Lv J, Wong MG, Hladunewich MA, et al. Effect of oral methylprednisolone on decline in kidney function or kidney failure in patients with IgA nephropathy: the TESTING randomized clinical trial. JAMA. 2022;327(19):1888–1898.
   PubMed Web of Science ®Google Scholar
• Beck N, Walz G, Schneider J. Effect of cyclophosphamide and glucocorticoid therapy in IgA nephropathy: a single-center retrospective analysis. Kidney360. 2022;3(3):506–515.
   PubMedGoogle Scholar
• Tumlin JA, Lohavicha V, Hennigar R. Crescentic, proliferative IgA nephropathy: clinical and histological response to methylprednisolone and intravenous cyclophosphamide. Nephrol Dial Transplant. 2003;18:3177–3183.
   Web of Science ®Google Scholar
• Hotta O, Furuta T, Chiba S, et al. Regression of IgA nephropathy: a repeat biopsy study. Am J Kidney Dis. 2002;39(3):493–502.
   PubMed Web of Science ®Google Scholar